Abstract
Background This study (ARVAC-F2-3-002) assessed the immunogenicity, safety, and tolerability of a recombinant booster vaccine (ARVAC) containing the receptor binding domain of the SARS-CoV-2 Spike protein in three different versions: Gamma (ARVACGamma), Omicron BA.4/5 (ARVACOmicron), and Gamma/Omicron Bivalent (ARVACBivalent).
Methods Randomized, double-blind, crossover, placebo-controlled, multicenter (11 centers in Argentina) Phase II/III trial including adult volunteers previously vaccinated against SARS-CoV-2 with ≤3 booster doses. Participants were randomized to receive ARVACGamma (50 µg)+placebo and vice-versa (1:1 ratio) (Phase II), and ARVACGamma (50 µg)+placebo, ARVACOmicron (50 µg)+placebo, and ARVACBivalent (Gamma/Omicron 25 µg/25 µg)+placebo and vice-versa (Phase III) (1:1:1:1:1:1 ratio) 28 days apart. The primary endpoint was the seroconversion rate of neutralizing antibodies compared to placebo. The vaccine immunogenicity was considered acceptable at >75% seroconversion rate to variants homologous to the antigen contained in the vaccine (prespecified primary endpoint).
Results Participants (n=2012) (mean 48.2 years, SD 16.7; 48.1% women) were randomized and allocated to ARVACGamma (n=232 in Phase II and n=592 in Phase III), ARVACOmicron (n=594), and ARVACBivalent (n=594); 232 in Phase II and 370 in each Phase III group were included in the immunogenicity subset. Seroconversion rates to all SARS-CoV-2 variants were significantly higher after receiving any vaccine than placebo. All vaccine versions met the prespecified primary endpoint in all participants and in those 18−60 years old. In participants >60 years, the ARVACOmicron and the ARVACBivalent met the prespecified primary endpoint, whereas the ARVACGamma did not. The ARVACBivalent induced seroconversion rates were significantly higher than 75% across all tested SARS- CoV-2 variants (homologous and heterologous) and age groups. No vaccine-related serious adverse events were recorded; most local and systemic adverse events were grade 1-2.
Conclusion Booster vaccination with Gamma, Omicron BA.4/5, and Bivalent protein subunit recombinant ARVAC vaccine versions elicited protective neutralizing antibody responses to several SARS-CoV-2 variants, with very low reactogenicity and a favorable safety profile.
Trial registration: NCT05752201
Competing Interest Statement
J.M.R., L.P.C. Group, F.M.O., J.C.V. and JoC are employees of Laboratorio Pablo Cassará S.R.L., which developed the vaccine. M.E.L. and J.F. are external consultants and received honoraria from Laboratorio Pablo Cassará S.R.L. G.PM has received a research grant from Merck and G.PM, A.B., V.M.B., A.Ch, S.C., M.C.D., L.DN., T.B.N., R.LP., C.G.M., LP, V.M.TU, C.J.W, and R.Z. conduct clinical trials for Pfizer, Merck, Sanofi, and Moderna, Inc. P.B. was investigator in clinical trials of Sinopharm and Janssen COVID-19 vaccines and was Advisory Board Participant for Moderna and Raffo. M.F.A. received honoraria for clinical research from Astra Zeneca, Pfizer, Dompé and Red Insight. N.I. received honoraria for clinical research GSK, Celcuity, Novartis, Genentech, Astra Zeneca, MSD, and Chiesi. S.A.N. received honoraria for clinical research from: GSK, AstraZeneca, Sanofi Aventis, Eli Lilly, NIAID, ATEA Pharmaceuticals and financial help to assist meetings and conferences from GSK, MSD, and Sanofi. O.R. was principal investigator in a clinical study of Merck. R.M.G. and F.B. are employees from Nobeltri S.R.L that offers services to Laboratorio Pablo Cassará S.R.L. All other authors declare no competing interests.
Clinical Trial
NCT05752201
Funding Statement
The trial was funded by the National ministry of Science and Technology and the National Agency for promotion of Science and Technology of Argentina.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants signed the informed consent form. The National Administration of Drugs, Food, and Medical Technology (Administración Nacional de Medicamentos, Alimentación y Tecnología Médica, ANMAT), the CABA Local Ethics Committee (PRIISA, Plataforma de Registro Informatizado de Investigaciones en Salud de Buenos Aires), and the Ethics Committee on Clinical Research (CEIC) of the Infectious Studies Center S.A. (Centro de Estudios Infectológicos, CEI) Stamboulián approved the protocol, which was prospectively registered at ANMAT, PRIISA, and clinicaltrials.gov (NCT05752201). The local Ethics Committees that approved the study protocol are: 1 Ethics Committee on Clinical Research (CEIC) of the Infectious Studies Center S.A. Comité de ética en Investigación Clínica (CEIC) del Centro de Estudios Infectologicos S.A. CEI Stamboulián. 2 Ethics Committee of the Medical Education and Clinical Investigations Center. Comité de ética en Investigación de CEMIC. 3 Research Ethics Committee. Clinical Research Institute Dr. Jesus Vazquez. DiMe Foundation. 4 Provincial Biomedical Research Commission. Comisión Provincial de Investigaciones Biomédicas. 5 Research Ethics Committee of the Platense Medical Institute. Comité de ética en Investigación Instituto Médico Platense (CEDIMP). 6 Institutional Medical Research Ethics Committee Fabiola Queen Fabiola. University Clinic. Comité Institucional de ética en Investigación en Salud CIEIS Fabiola. Clínica Universitaria Reina Fabiola. 7 Bioethics Committee (Research Ethics Committee) of the Huesped Foundation. Comite de Bioética de la Fundación Huésped.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as clinicaltrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
